EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies

Ashutosh Pareek iD, Lipika Kumari, Lance R McMahon, Anil Chuturgoon iD, Aaushi Pareek

Pharmaceutics · 12.04.2026 · 18 (4) · 469

DOI: 10.3390/pharmaceutics18040469 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 12.04.2026. Verfasst von Ashutosh Pareek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Banasthali Vidyapith, Banasthali 304022, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabinoids (CBs) derived from Cannabis sativa have attracted growing interest for dermatological applications due to their anti-inflammatory, antiproliferative, antimicrobial, antifibrotic, and antipruritic properties. However, their clinical translation is significantly limited by physicochemical and pharmacokinetic challenges, including poor aqueous solubility, lipophilicity, instability, variable skin penetration, and inconsistent bioavailability. At the molecular level, CBs modulate keratinocyte proliferation, sebocyte activity, fibroblast function, melanocyte balance, and immune signalling through CB1/CB2 receptors, TRP channels, and PPARγ pathways. Evidence supports their potential in the treatment of psoriasis, atopic dermatitis, acne, allergic contact dermatitis, pruritus, scleroderma, and skin cancers. Clinical evidence remains preliminary: topical and oral formulations have demonstrated anti-inflammatory, antiproliferative, antibacterial, and antifibrotic effects, with improvements in pruritus, lesion severity, and quality of life in early-phase studies. However, most trials are small, uncontrolled, and lack placebo comparators, limiting generalisability. To overcome formulation barriers and enhance dermal delivery, advanced pharmaceutical strategies such as liposomes, nanoemulsions, polymeric nanoparticles, micelles, and transdermal systems have been investigated to improve stability, controlled release, and targeted skin deposition while minimising systemic exposure. This review integrates mechanistic insights, clinical evidence, and emerging nanotechnology-enabled delivery approaches, emphasising rational formulation design and translational considerations necessary for advancing CBs toward standardised and clinically reliable dermatological therapeutics.

Schlagwörter

Stichwörter der Autor:innen

atopic dermatitiscannabidioldermatologynanotechnologypsoriasisskin cancer

Autor:innen und Institutionen

  • Department of Pharmacy, Banasthali Vidyapith, Banasthali 304022, India.
  • Department of Bioscience and Biotechnology, Banasthali Vidyapith, Banasthali 304022, India.
  • Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
  • Discipline of Medical Biochemistry, School of Medicine, University of KwaZulu-Natal, Durban 4041, South Africa.

ORCID-Profile: Ashutosh Pareek, Anil Chuturgoon

Zitieren

APA

Pareek, A., Kumari, L., McMahon, L. R., Chuturgoon, A., & Pareek, A. (2026). Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. Pharmaceutics, 18(4), 469. https://doi.org/10.3390/pharmaceutics18040469

Vancouver

Pareek A, Kumari L, McMahon LR, Chuturgoon A, Pareek A. Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. Pharmaceutics. 2026;18(4):469. doi:10.3390/pharmaceutics18040469

BibTeX
@article{Pareek2026,
  author = {Pareek, Ashutosh and Kumari, Lipika and McMahon, Lance R and Chuturgoon, Anil and Pareek, Aaushi},
  title = {Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {469},
  doi = {10.3390/pharmaceutics18040469}
}
Kostenlos starten →